Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hoechst PakistanKAR:HPL -1.37%88 EV-to-OCF is 9.18 as of Aug. 18, 2026, which is 12% above its 10-year median of 8.18. GuruFocus rates KAR:HPL with a GF Score™ of 88/100 and a GF Value™ of ₨3,336.19 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Hoechst Pakistan ranks better than 53.63% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Hoechst Pakistan's Enterprise Value is ₨34,873 Mil.
Hoechst Pakistan's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was ₨3,800 Mil. Therefore, Hoechst Pakistan's EV-to-OCF for today is 9.18.
The historical rank and industry rank for Hoechst Pakistan's EV-to-OCF or its related term are showing as below:
KAR:HPL'
s EV-to-OCF Range Over the Past 10 Years
Min: -267.87 Med: 8.18 Max: 269.24
Current: 9.32
During the past 13 years, the highest EV-to-OCF of Hoechst Pakistan was 269.24. The lowest was -267.87. And the median was 8.18.
KAR:HPL's EV-to-OCF is ranked better than 53.63% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 11
vs KAR:HPL: 9.32
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Hoechst Pakistan's PE Ratio (TTM) for today is calculated as:
Hoechst Pakistan's share price for today is ₨3930.45.
Hoechst Pakistan's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨316.990.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Hoechst Pakistan EV-to-OCF Related Terms
Hoechst Pakistan EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Hoechst Pakistan's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Hoechst Pakistan's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hoechst Pakistan EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hoechst Pakistan's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Hoechst Pakistan's EV-to-OCF falls into.
Hoechst Pakistan's current Enterprise Value is ₨34,873 Mil.
Hoechst Pakistan's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨3,800 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hoechst Pakistan (KAR:HPL) has a EV-to-OCF of 9.18 as of Aug. 18, 2026. This is 12% above median its historical median of 8.18. According to the industry distribution chart, Hoechst Pakistan ranks #466 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 46.4%.
Is Hoechst Pakistan's EV-to-OCF too high?
Hoechst Pakistan's current EV-to-OCF of 9.18 is 12% above median its 10-year median of 8.18. The Drug Manufacturers industry median EV-to-OCF is 11.00. Hoechst Pakistan's value of 9.18 is 16.5% below this industry median. Based on the distribution chart, Hoechst Pakistan ranks #466 out of 1005 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hoechst Pakistan has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hoechst Pakistan's EV-to-OCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Hoechst Pakistan ranks #466 out of 1005 companies for EV-to-OCF. This puts Hoechst Pakistan in the upper half of its industry. The industry median EV-to-OCF is 11.00. Hoechst Pakistan's value of 9.18 is 16.5% below this benchmark. While the company's 10-year median is 8.18 vs. the industry median of 11.00, Hoechst Pakistan has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.00, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hoechst Pakistan's current EV-to-OCF of 9.18 is 16.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hoechst Pakistan's current EV-to-OCF is 9.18, which is 12% above median its own 10-year median of 8.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hoechst Pakistan stock overvalued right now?
Based on GuruFocus' analysis, Hoechst Pakistan (KAR:HPL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₨3,336.19, compared to a current price of ₨3,930.45 — trading 17.8% above its estimated fair value. The current EV-to-OCF is 9.18, which is 12% above median its 10-year median of 8.18 and 16.5% below the Drug Manufacturers industry median of 11.00. Hoechst Pakistan's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Hoechst Pakistan (KAR:HPL), the current EV-to-OCF is 9.18 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hoechst Pakistan (KAR:HPL) Overvalued in 2026?
Based on GuruFocus' analysis, Hoechst Pakistan stock appears to be overvalued.
The current stock price of ₨3,930.45 is trading 17.8% above its estimated GF Value™ of ₨3,336.19.
GuruFocus considers Hoechst Pakistan to be Modestly Overvalued.
Key valuation signals for KAR:HPL:
EV-to-OCF: 9.18 (12% above median its 10-year median of 8.18)
GF Value™: ₨3,336.19 vs. price of ₨3,930.45 (17.8% above fair value)
Industry Position: 16.5% below the Drug Manufacturers median (#466 of 1005)
No single metric tells the full story. See the KAR:HPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hoechst Pakistan Ltd is a healthcare company of Pakistan, focused on patient needs and engaged in the manufacturing, promotion, and sale of pharmaceutical and vaccines. The company engages in the manufacturing, selling and trading of pharmaceutical and related products.
88GF Score
Get the complete analysis for KAR:HPL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:HPL has been successfully added to your 
